Standout Papers

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III... 2015 2026 2018 2022 306
  1. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study (2015)
    James M. Schuster, Lawrence D. Recht et al. Neuro-Oncology

Immediate Impact

8 by Nobel laureates 27 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Hallmarks of aging: An expanding universe
2023 Standout
Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras
2023 StandoutScienceNobel
2 intermediate papers

Works of Thomas A. Davis being referenced

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
2015
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
2014
and 1 more

Author Peers

Author Last Decade Papers Cites
Thomas A. Davis 702 607 750 750 73 3.1k
Jean Michel Foidart 586 345 1149 1252 69 4.0k
Margherita Massa 766 865 1350 424 101 3.6k
Kazuhisa Nakano 1515 481 859 570 133 3.5k
Christian Hagel 410 688 1125 372 193 3.9k
Anne E. Hughes 367 148 1003 563 56 3.0k
Anthony Béhin 349 754 1584 357 142 3.8k
Marieke J. H. Coenen 689 234 963 334 123 2.8k
P. Martin van Hagen 370 119 688 582 130 3.5k
Richard S. Camplejohn 338 136 1022 1043 62 3.1k
Lois J. Arend 489 221 1104 328 102 4.5k

All Works

Loading papers...

Rankless by CCL
2026